Therapeutic Genome Editing Congress | Kisaco Research
Progressing Clinical Development and Commercialisation of Therapeutic Genome Editing Applications
Boston, USA
20-21 March, 2019
Download Agenda
The Audience
Register

Why Attend

With the first phase I/II CRISPR human clinical trial being approved within the US and Europe earlier this year, genome editing technology continues to race through biotech pipelines. The time has come to address and resolve clinical and critical application issues as we get closer to genome editing as a commercial medicine.

The Therapeutic Genome Editing Congress will connect peers from biotech, pharma, academia, and genome editing technology developers along with experts from government bodies, medical institutions and commercial consultants to define how to actively progress clinical development.

Our speakers will explore ground-breaking developments surrounding CRISPR and utilising all genome editing tools as a therapy. It will focus on advancements to overcome ‘off targets’, delivery approaches for in vivo applications and efficacy considerations across patient diversity. Topics will include:

  • CRISPR Therapeutics and Cellectis will share their clinical trial experiences within therapeutic genome editing applications 
  • Harvard’s Richard Sherwood will share how to improve CRISPR safety by utilizing machine learning
  • Casebia will offer delivery guidance to progress in vivo applications

The event will provide the opportunity for multidisciplinary collaboration to create a clinically and commercially viable, effective and safe approach within gene and cell therapy medicine. 

 ‘CRISPR medicines have the potential to transform the treatment for rare genetic and perhaps common diseases; the challenge for scientists is to demonstrate that these medicines can be both safe and effective’ – Steve Rees, VP of Disruptive Biology, AstraZeneca

Talk to Our Speakers About...

1. How to overcome off- targets through base editing and utilizing new Cas strains

2. New delivery systems to approach successful in vivo applications

3. How does patient diversity impact CRISPR efficacy?

4. Industry’s thoughts on the future of CRISPR/Cas tool in a therapeutic setting

5. How to apply genome editing and protocols for successful clinical trials

6. Key translational science skills essential for clinical development

7. The commercial viability of genome editing as a medicine, what are medical institutions looking for?

8. IP and licencing landscape surrounding genome editing tools to progress commercially 

9. Rational analysis of risk benefit and disease identification 

10. Ethical factors

Who Will Be There

30%
Biotechs
20%
Pharma
15%
Academics
10%
Clinicians & Physicians
15%
Service Providers

Biotechs

Pharma

Academics

Clinicians & Physicians

Service Providers

Genome Editing Platform Technologies

The Speakers

 

Niren Murthy

Professor
UC Berkeley

Niren Murthy

Professor
UC Berkeley
 

David Resnick

Patent Attorney
Nixon Peabody

David Resnick

Patent Attorney
Nixon Peabody
 

Samantha Maragh

Leader of Genome Editing Program
NIST

Samantha Maragh

Leader of Genome Editing Program
NIST
 

Eric Kmiec

Director of Gene Editing Institute
Christiana Care Health

Eric Kmiec

Director of Gene Editing Institute
Christiana Care Health
 

Abraham Scaria

Vice President & Head of Ophthalmology
Casebia

Dr. Scaria obtained his Ph.D. in Molecular Biology from Indiana University School of Medicine in Indianapolis. He did postdoctoral training at St. Louis University School of Medicine working on RNA splicing mechanisms in adenoviruses and virus-host interactions. Dr. Scaria then worked as a Senior Fellow at University of Washington School of Medicine in Seattle before joining Genzyme Corporation to work on gene therapy for Cystic Fibrosis. At Genzyme and later at Sanofi-Genzyme, Dr.

Abraham Scaria

Vice President & Head of Ophthalmology
Casebia

Dr. Scaria obtained his Ph.D. in Molecular Biology from Indiana University School of Medicine in Indianapolis. He did postdoctoral training at St. Louis University School of Medicine working on RNA splicing mechanisms in adenoviruses and virus-host interactions. Dr. Scaria then worked as a Senior Fellow at University of Washington School of Medicine in Seattle before joining Genzyme Corporation to work on gene therapy for Cystic Fibrosis. At Genzyme and later at Sanofi-Genzyme, Dr. Scaria held various positions with increasing responsibilities for two decades finally heading up both the gene therapy research group and the ophthalmology research efforts. Currently, Dr. Scaria is the VP & Head of Ophthalmology at Casebia Therapeutics where he is developing gene-editing based therapies for ocular genetic diseases.

 

Richard Sherwood

Professor
Harvard University

My lab combines high-throughput genomic screening with machine learning to understand genome function in normal and diseased contexts. My work aims to advance precise genomic medicine and novel gene therapy applications.

Richard Sherwood

Professor
Harvard University

My lab combines high-throughput genomic screening with machine learning to understand genome function in normal and diseased contexts. My work aims to advance precise genomic medicine and novel gene therapy applications.

 

George Church

Professor
Harvard

George Church

Professor
Harvard
 

TJ Cradick

Head of Genome Editing
CRISPR Therapeutics

TJ Cradick

Head of Genome Editing
CRISPR Therapeutics
 

Stefan Scherer

SVP Clinical Development
Cellectis

Stefan Scherer

SVP Clinical Development
Cellectis
 

Steve Rees

VP of Disruptive Biology
AstraZeneca

Steve Rees is Vice-President of the Discovery Biology department at AstraZeneca with global responsibility for reagent generation, assay development and functional genomics.  Prior to this Steve led the Screening Sciences and Sample Management department at AstraZeneca with accountability  for Compound Management, the human tissue BioBank, Hit Discovery and Lead Optimisation biology support to preclinical discovery projects.  Prior to joining AstraZeneca, Steve worked at GlaxoSmithKline for 24 years in various roles.   Steve has led multiple international collaborations, has authored >65

Steve Rees

VP of Disruptive Biology
AstraZeneca

Steve Rees is Vice-President of the Discovery Biology department at AstraZeneca with global responsibility for reagent generation, assay development and functional genomics.  Prior to this Steve led the Screening Sciences and Sample Management department at AstraZeneca with accountability  for Compound Management, the human tissue BioBank, Hit Discovery and Lead Optimisation biology support to preclinical discovery projects.  Prior to joining AstraZeneca, Steve worked at GlaxoSmithKline for 24 years in various roles.   Steve has led multiple international collaborations, has authored >65 scientific papers and has spoken at many international symposia.  He is currently Chairman of the European laboratory Research and Innovation Group, and a member of the Scientific Advisory Board for LifeArc, the Centre for Membrane Protein Receptor Research at the Universities of Birmingham and Nottingham and Axol Bioscience Ltd.

 

Dr. Alessandra Biffi

Director, Gene Therapy Program
Boston Children’s Hospital

Dr. Alessandra Biffi

Director, Gene Therapy Program
Boston Children’s Hospital
 

Dr Claudio Mussolino

CCI Junior Group Leader
Medical Center – University of Freiburg

Dr Claudio Mussolino

CCI Junior Group Leader
Medical Center – University of Freiburg
 

Professor Jeff Chamberlain

Professor, Depts. of Neurology, Medicine and Biochemistry
University of Washington

Professor Jeff Chamberlain

Professor, Depts. of Neurology, Medicine and Biochemistry
University of Washington
 

Dr Gurumurthy Channabasavaiah

Director of Mouse Genome Engineering Core Facility
University of Nebraska Medical Center

Guru (CB Gurumurthy) received his BVSC (DVM) from Bangalore Veterinary College, India and MVSC & PHD in Veterinary Virology from Indian Veterinary Research Institute, with a Gold Medal distinction in MVSC, and an Executive MBA from University of Nebraska at Omaha. He is currently an Associate Professor of Developmental Neuroscience, Munroe Meyer Institute for Genetics and Rehabilitation at the University of Nebraska Medical Center. He is also the Director of the UNMC’s Mouse Genome Engineering Core Facility.

Dr Gurumurthy Channabasavaiah

Director of Mouse Genome Engineering Core Facility
University of Nebraska Medical Center

Guru (CB Gurumurthy) received his BVSC (DVM) from Bangalore Veterinary College, India and MVSC & PHD in Veterinary Virology from Indian Veterinary Research Institute, with a Gold Medal distinction in MVSC, and an Executive MBA from University of Nebraska at Omaha. He is currently an Associate Professor of Developmental Neuroscience, Munroe Meyer Institute for Genetics and Rehabilitation at the University of Nebraska Medical Center. He is also the Director of the UNMC’s Mouse Genome Engineering Core Facility. His research interests are improving and development of novel genome engineering technologies. He is a co-developer of popular technologies such as Easi (Efficient additions with ssDNA-inserts)-CRISPR, CRISPR-first: PITT-next and GONAD (Genome Editing via Oviductal Nucleic Acids Delivery). Some of these technologies have already been adapted in many labs worldwide.

 

Dr Andrew Kernytsky

Head of Computational Biology
CRISPR Therapeutics

Dr Andrew Kernytsky

Head of Computational Biology
CRISPR Therapeutics
 

Issi Rozen

Chief Business Officer
Broad Institute

ISSI ROZEN, Chief Business Officer at the Broad Institute of Harvard and MIT, is responsible for partnering with the life sciences industry and venture investors and developing innovative scientific and business collaborations. He is also responsible for initiating and establishing new ventures around novel technologies and for licensing the institute’s intellectual property portfolio. He joined the Broad in 2011 after a career in the biotech industry. Before joining the Broad Institute, Rozen led corporate development at Resolvyx, a venture-backed biotech start-up.

Issi Rozen

Chief Business Officer
Broad Institute

ISSI ROZEN, Chief Business Officer at the Broad Institute of Harvard and MIT, is responsible for partnering with the life sciences industry and venture investors and developing innovative scientific and business collaborations. He is also responsible for initiating and establishing new ventures around novel technologies and for licensing the institute’s intellectual property portfolio. He joined the Broad in 2011 after a career in the biotech industry. Before joining the Broad Institute, Rozen led corporate development at Resolvyx, a venture-backed biotech start-up. Before that, he headed the business analysis group at EMD Serono where he was responsible for evaluations of in-licensing and M&A opportunities as well as commercial analytics and forecasting for pipeline and commercial products. Issi is a co-founder of a number of biotech start-ups and is an accomplished jazz guitarist. He earned his M.B.A. at MIT’s Sloan School of Management.

The Agenda

Please download the agenda to find out more information about the congress including the main topics of discussion for the two days and our full lineup of speakers.

What you can expect from the Therapeutic Genome Editing congress:

  • 150+ participants from academic, industry, biotech and regulatory bodies onsite
  • Thought leaders on the speaking agenda and ready to answer your big questions
  • 2 days of furthering therapeutic genome editing

Therapeutic Genome Editing Congress

Watch Highlights from the European Microbiome Congress 2018

Watch Highlights from Human & Animal Health Boston 2018

Download Agenda

We need some information to know where to send the link and how to address our email to you. Please note, a link to the PDF will also become immediately available once this form is submitted.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

Become a Sponsor

Kisaco Research provides the much needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.

Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.

Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].

Venue

Boston, USA

Venue will be confirmed shortly.

Conference Packages

Sending Your Team? Group Discounts Available!

Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates

Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off

If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920

Tuesday, November 20, 2018 to Friday, January 18, 2019
SUPER EARLY BIRD - ACADEMICS, GOVERNMENT & CLINICIANS
$799
Super Early Bird available through January 18, 2019. Save $200
Main Conference Sessions & Networking Functions
Tuesday, November 20, 2018 to Friday, January 18, 2019
SUPER EARLY BIRD - BIOTECH AND PHARMA (ACTIVE PIPELINE)
$1499
Super Early Bird available through January 18, 2019. Save $400
Main Conference Sessions & Networking Functions
Tuesday, November 20, 2018 to Friday, January 18, 2019
SUPER EARLY BIRD - VENDOR
$1899
Super Early Bird available through January 18, 2019. Save $400
Main Conference Sessions & Networking Functions
Preparing registration...

About Kisaco Research

Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.

Meet industry peers that will help build a career-changing network for life.

Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.

Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.

Invest both in your company growth and your own personal development by signing up to one of our events and get started.

Contact Us

We need some information to know how best to respond to your request below.

To prevent automated spam submissions leave this field empty.

Subject Access Requests: If you would like a copy of the data/information we hold about you, please email [email protected].

User Deletion Request: If you wish to have your information that is held by Kisaco Research deleted, please email [email protected].

For more information on Kisaco Research policy and procedures, please visit our Privacy Policy.

Other events you might be interested in:

CAR-T Congress EU 2019